NCT01443442View on ClinicalTrials.gov

Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis

PHASE4CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

September 30, 2012

Study Completion Date

December 31, 2012

Conditions
Allergic Conjunctivitis
Interventions
DRUG

bepotastine besilate, 1.5%

Topical ocular aqueous formulation, oen drop per instillation, twice per day for 14 days

DRUG

Loteprednol etabonate

Topical ocular aqueous formulation, one drop per instillation, four times per day for 14 days

Trial Locations (2)

92831

Eye Car Center, Southern California college of Optometry, Fullerton

Eye Care Center, Southern Caalifornia College of Optometry, Fullerton

All Listed Sponsors
lead

Southern California College of Optometry at Marshall B. Ketchum University

OTHER

NCT01443442 - Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis | Biotech Hunter | Biotech Hunter